The modern treatment of heart failure is characterized by early intervention, multidimensional care and extended therapy options. Around half of all heart failure patients have a reduced left ventricular ejection fraction. With regard to drug therapy, according to ESC guidelines, there are four standard recommended drug classes that should be used early in HFrEF, as they are particularly important for reducing morbidity and mortality. SGLT-2 inhibitors are now recommended for HFrEF, HFmrEF and HFpEF.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Digital dermatology: innovative project examples
AI and eHealth tools in HS care
- Mantle cell lymphoma
Recurrence after BTK inhibition – prognostic factors and treatment options
- Dementia risk with type 2 diabetes
SGLT2 inhibitors with advantages vs. DPP4 inhibitors
- T helper 1 cells
Differentiation and activation of Th1 cells – a multi-omics approach
- Cannabis for schizophrenia
CBD pre-treatment could exacerbate side effects
- Type 2 diabetes: cardiovascular risk reduction is realistic
Modern active ingredients and lifestyle – every step counts
- Case study
8-year-old girl with Pätau syndrome aka trisomy 13
- Lichen sclerosus